Drug Discovery World

OCTOBER 3, 2023

Earlier this year, DDW hosted a webinar, ‘A comprehensive guide to using adeno-associated virus (AAV) vectors in gene therapy’, supported by Azenta Life Sciences. AAV is optimal for gene therapy due to its efficiency and safety in humans; however, AAV processes can present obstacles for researchers.

Gene Therapy 52

Gene Therapy Gene Life Science Bioinformatics 52

Cloudbyz

SEPTEMBER 10, 2023

The challenge of managing and securing sensitive data, including PHI and PII, is significant for life sciences organizations. Additionally, the consequences of data breaches can be severe for life sciences organizations. The challenge is further compounded by the need for fast and accurate analysis of data.

Life Science 95

Life Science Regulation Production Marketing 95

XTalks

DECEMBER 13, 2023

The US Food and Drug Administration (FDA) has approved the first gene therapies for the treatment of sickle cell disease, approving two on the same day. Both gene therapies are approved for individuals 12 years of age and older with sickle cell disease. How do Casgevy and Lyfgenia Work?

Gene Therapy 98

Gene Therapy FDA Approval Gene In-Vivo 98

XTalks

DECEMBER 29, 2022

The life sciences and healthcare are among the biggest industries globally, and their significance was particularly highlighted during the past couple of years by the COVID-19 pandemic. Given the hyperfocus on the life sciences thanks to COVID, consumers appear to be more autonomous and vocal about their medical demands and choices.

Life Science 52

Life Science Gene Therapy Gene Manufacturing 52

Drug Discovery World

DECEMBER 8, 2023

Andrew Busey , Co-Founder, Form Bio discusses why vertical AI is set to reshape the cell and gene therapy sector. The cell and gene therapy industry is no exception to this digital transformation. Here’s what this means for pharmaceutical leaders and patients.

Gene Therapy 64

Gene Therapy Gene In-Vitro Development 64

Drug Discovery World

MARCH 16, 2023

The cell and gene therapy (CGT) market is rapidly expanding, and projections suggest it will reach over $90B by 2023. Challenges of cell and gene therapy manufacturing Compared to traditional biologics, CGTs are living drugs, making their development and manufacturing substantially more complex.

Gene Therapy 52

Gene Therapy Gene Manufacturing Life Science 52

XTalks

APRIL 24, 2023

Awareness of rare diseases is growing, and with a better understanding of the pathophysiology of many rare diseases, innovative treatment options are emerging, like gene therapies that can treat the root cause of rare genetic diseases and potentially provide long-term symptom relief, or even a definitive cure.

Gene Therapy 95

Gene Therapy Gene Trials Clinical Trials 95

Pharmaceutical Technology

NOVEMBER 23, 2022

Innovations in biotechnology are advancing the biopharmaceutical market, enabling the treatment of complex diseases with next-generation therapeutics synthesised or extracted from a biological source. With around 35,000 employees, the broader life sciences sector is one of Hamilton’s largest industries.

Marketing 130

Marketing Gene Therapy Life Science Manufacturing 130

Drug Discovery World

NOVEMBER 24, 2022

With European life sciences R&D investment at a 20-year low, biopharmaceutical associations and MEPs are calling on the EU to modernise its policies. DDW’s Diana Spencer asks what will be needed for Europe to compete in the growing global market for advanced therapies. . Developing world class innovation hubs.

Gene Therapy 98

Gene Therapy Gene Clinical Trials Clinical Trials 98

XTalks

DECEMBER 20, 2023

In 2023, there were significant advancements and notable trends in the life sciences. Xtalks compiled a list of its top life science news and trends of 2023, which provided readers with the latest developments, information and expert insights across life science industries, including pharma, biotech and medical device.

Life Science 59

Life Science Clinical Trials Clinical Trials FDA Approval 59

Drug Discovery World

MAY 23, 2023

DDW’s Megan Thomas caught up with George White , General Manager, Product Management, Cell & Gene Therapy at Cytiva, to learn more about the company’s insight into the CGT market. We’re seeing a drive towards the allogeneic market with more progressing into clinical trials.

Gene Therapy 52

Gene Therapy Gene Gene Editing Production 52

Drug Discovery World

JULY 11, 2022

David Lewandowski, Business Director of Cell & Gene Therapy at Azenta Life Sciences, explains how efficient sample management can help to work efficiently and bring therapies to market faster. It has been estimated that by 2025 the FDA will be approving 10 to 20 cell and gene therapy products per year 2.

Gene Therapy 52

Gene Therapy Gene Development Production 52

Drug Discovery World

SEPTEMBER 6, 2022

In recent years the advanced therapy industry has been the most significant disruptor in medicine. Cell and gene therapies are not only transforming the way diseases are treated but are also aiming to cure entirely new patient populations. ViaCyte, Beam, and Verve are all due to begin gene editing trials this year.

Gene Therapy 52

Gene Therapy Gene Gene Editing Manufacturing 52

BioPharma Reporter

AUGUST 14, 2023

Teknova, a producer of life science reagents, has opened a new GMP-certified production facility which it claims will enable bioprocessing and gene therapy companies to get into the clinic faster.

Reagent 98

Reagent Gene Therapy Life Science Manufacturing 98

BioPharma Reporter

JULY 3, 2023

Donaldson, a provider of filtration products and solutions, has acquired Univercells Technologies, a producer of biomanufacturing solutions for cell and gene therapy research, development, and commercial manufacturing, to broaden its life sciences reach.

Gene Therapy 97

Gene Therapy Life Science Gene Manufacturing 97

Cloudbyz

MAY 19, 2021

Introduction Cell and gene therapy is an upcoming wave of therapeutic innovation in the healthcare and life sciences industry and is being pragmatically accepted worldwide. The gene therapy market reported its first market approvals back in 2017 and the evolution has been extensive ever since.

Gene Therapy 52

Gene Therapy Gene Manufacturing Production 52

Drug Discovery World

MAY 22, 2023

Ryan Leahy , a science communication expert in cell and gene therapy, at Phacilitate, says there is a lot to celebrate but also much to assess, question and challenge in this sector. Its subsequent success with approval in the US shows us that some drugs will be unavailable to some markets and patients for now.

Gene Therapy 52

Gene Therapy Gene Drugs Contamination 52

XTalks

OCTOBER 4, 2023

Health economics and outcomes research (HEOR) and market access strategies play a critical role in ensuring that newly approved therapies are made available to patients. Professionals in these roles are facing new challenges when it comes to negotiating coverage for many of the new, innovative treatments that are coming to market.

Marketing 105

Marketing Development Drugs Gene Therapy 105

The Pharma Data

OCTOBER 26, 2020

The agreement covers the gene therapy program targeting OTOF (OTOF-GT), the gene encoding the otoferlin protein. Sensorion is currently advancing two preclinical gene therapy programs conducted under a broad multi-program research partnership with the Genetics and Physiology of Hearing Unit at Institut Pasteur (Paris).

Gene Therapy 52

Gene Therapy Gene Manufacturing Production 52

Drug Discovery World

SEPTEMBER 6, 2022

DDW Editor Reece Armstrong looks at the cell and gene therapy landscape, examining the challenges facing developers and the trends we can expect to see throughout the year. . There’s no doubt that cell and gene therapies present some of the most exciting opportunities for emerging drugs. million price point per dose.

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52

Drug Channels

OCTOBER 19, 2020

16th Annual Life Sciences Trade and Channel Strategies. Medical Plus – Tailored Track Options Based on Company Size : Emerging/Small Companies – Infrastructure Set-Up, License Procurement and 3PL Contracting Mid-Large Companies – How Do I Think About My Portfolio Differently Based on Product Type?

Life Science 52

Life Science Pharmacy Gene Therapy Gene 52

XTalks

DECEMBER 27, 2022

Adstiladrin is an adenoviral vector-based gene therapy that is non-replicating, so it cannot multiply in human cells. The pharma company will expand its manufacturing capacity for commercial scale vector production for oncology treatment. How Does the Gene Therapy Adstiladrin Work?

Gene Therapy 52

Gene Therapy FDA Approval Gene Clinical Trials 52

Drug Channels

NOVEMBER 8, 2020

16th Annual Life Sciences Trade and Channel Strategies. That’s why the life science industry’s top experts will come together virtually on December 1-3 at Trade and Channel 2020. December 1-3, 2020 | Virtual Event www.informaconnect.com/trade-channel. Stuart Parker, Senior Director, Trade Relations, Mayne Pharma And more!

Life Science 52

Life Science Pharmacy Gene Therapy Branding 52

XTalks

JUNE 12, 2023

Bristol Myers Squibb (BMS), a multinational pharmaceutical company based in New York City, has announced that its new state-of-the-art cell therapy manufacturing facility in Devens, Massachusetts, has received approval for commercial production from the US Food and Drug Administration (FDA).

Manufacturing 95

Manufacturing Gene Therapy FDA Approval Gene 95

Drug Discovery World

MAY 24, 2023

IB Communications’ CEO Michelle Boxall explains why there are two sides to the cell and gene therapy coin. With 2023’s financial outlook and predictions for the CGT market, there are two sides to this coin. Deliverables, whether they be clinical progress or new products and services, must be on time, efficient and clear.

Gene Therapy 52

Gene Therapy Life Science Gene Sales 52

pharmaphorum

OCTOBER 4, 2022

The life sciences company Solid Biosciences is merging with the privately-held gene therapy company AavantiBio in a deal which is expected to result in a combined sum of $215 million in cash and investments – projected to be enough for funding into 2025. This is due to close concurrently with the merger.

Gene Therapy 115

Gene Therapy Gene Life Science Genetics 115

Drug Discovery World

JULY 20, 2023

They are called “ A deal in the making ”, “ Why project management holds the key to efficient drug development ”, and “ Transcending expectations for cell & gene therapy development ”. In the first article, Drug Discovery World Editor Reece Armstrong looks at how a number of deals in pharma have sparked excitement in the industry.

Gene Therapy 40

Gene Therapy Drugs Gene Life Science 40

Drug Discovery World

MAY 6, 2024

Thanks to a prestigious academic legacy, Europe has long been a dominant region for life sciences. Europe is traditionally a life sciences powerhouse, with a strong tradition in pharmaceutical discovery. The oldest, still active pharmaceutical company worldwide, Merck, started life in 1668 in Darmstadt, Germany.

Drugs 59

Drugs Life Science Gene Editing Gene 59

Pharmaceutical Technology

JANUARY 12, 2023

The company stated that the collaboration would allow Phlox Therapeutics to deliver its RNA therapies to the heart by leveraging the vector biology and manufacturing capacities of Solid Biosciences. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. By Cytiva Thematic.

RNA 130

RNA Gene Therapy Genetics Genetic Disease 130

Drug Discovery World

FEBRUARY 19, 2024

Financial landscape In 2023, life science companies experienced a significant decrease in funding, particularly seed funding for early-stage drug development. This has been a real cause for concern for the industry, which is also facing growing competition in the investment market from big tech and AI.

Development 59

Development Gene Therapy Drugs Antibody 59

Drug Discovery World

FEBRUARY 12, 2024

“In the upcoming year, we will see the expansion of new, more complex markets and updated requirements from regulators. Without fixing the current, broken PV models, the continuous cycle of more complexity in the market, which then pushes organisations to incorporate automation into insufficient processes, will massively hinder PV operations.

Genome 139

Genome Genomics Life Science Gene Therapy 139

Drug Discovery World

FEBRUARY 10, 2023

DDW Editor Reece Armstrong explores the Scandinavian drug discovery sector and speaks to key players about Sweden’s place in the market. Scandinavia represents one of the most exciting but perhaps underrepresented markets for the discovery and development of pharmaceuticals.

Life Science 52

Life Science Drugs Gene Therapy Manufacturing 52

Drug Discovery World

JULY 20, 2023

They are called “ A deal in the making ”, “ Why project management holds the key to efficient drug development ”, and “ Transcending expectations for cell & gene therapy development ”. In the first article, Drug Discovery World Editor Reece Armstrong looks at how a number of deals in pharma have sparked excitement in the industry.

Gene Therapy 40

Gene Therapy Drugs Life Science Gene 40

pharmaphorum

SEPTEMBER 30, 2022

The stable of PD-1/PD-L1 checkpoint inhibitors, led by Keytruda (pembrolizumab), represents the current generation of high value, high price drugs to tackle a variety of cancers in mono- or combination therapy. sugemalimab) to market at “radically lower”, disruptive price points when compared to current options1.

Life Science 98

Life Science Marketing Drugs Production 98

Drug Discovery World

OCTOBER 16, 2023

Dr Salako says there are some clear fields of work associated with different areas, which include: Hertfordshire as a cell and gene therapy hub, with a number of companies in this space clustered around Stevenage. The UK, and specifically Wales, has been hugely supportive of life sciences and building a highly collaborative network.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

XTalks

MARCH 13, 2024

Related: Transforming Eye Care: Innovating New Glaucoma and Dry Eye Disease Treatments — Featuring Pierre Simon, VP Marketing, Sight Sciences – Xtalks Life Science Podcast Ep. There are also studies examining gene therapy-based techniques to repair or replace genetic defects contributing to this disease.

Gene Therapy 111

Gene Therapy Gene Life Science DNA 111

pharmaphorum

MARCH 10, 2022

Biologics product development has increased steadily over the past decade, with the volume of business forecast to double by 2030. Driven by advancements in technology, these complex therapeutics have already made waves in life sciences, providing revolutionary treatment options in oncology, immune conditions and rare diseases.

Production 98

Production Life Science Development Gene Therapy 98